Vera Therapeutics Files 8-K
Ticker: VERA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
TL;DR
Vera Therapeutics filed a routine 8-K, no major news.
AI Summary
Vera Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Vera Therapeutics is meeting its SEC reporting obligations, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no new material information or significant financial disclosures.
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2000 Sierra Point Parkway, Suite 1200 (address) — Principal executive offices
- Brisbane, California (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated in the filing details.
When was this 8-K report filed?
This 8-K report was filed on January 13, 2025.
What is Vera Therapeutics, Inc.'s state of incorporation?
Vera Therapeutics, Inc. is incorporated in Delaware.
What is the address of Vera Therapeutics, Inc.'s principal executive offices?
The address of Vera Therapeutics, Inc.'s principal executive offices is 2000 Sierra Point Parkway, Suite 1200, Brisbane, California, 94005.
Does this filing announce any new material events or financial results?
Based on the provided text, this filing appears to be a routine report and does not explicitly announce any new material events or specific financial results beyond standard disclosures.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2025-01-13 08:06:19
Key Financial Figures
- $0.001 — which registered Class A common stock, $0.001 par value per share VERA The Nasdaq
Filing Documents
- d921303d8k.htm (8-K) — 26KB
- d921303dex991.htm (EX-99.1) — 35KB
- g921303ex99_1p10g1.jpg (GRAPHIC) — 296KB
- g921303ex99_1p11g1.jpg (GRAPHIC) — 231KB
- g921303ex99_1p12g1.jpg (GRAPHIC) — 175KB
- g921303ex99_1p13g1.jpg (GRAPHIC) — 390KB
- g921303ex99_1p14g1.jpg (GRAPHIC) — 230KB
- g921303ex99_1p15g1.jpg (GRAPHIC) — 239KB
- g921303ex99_1p16g1.jpg (GRAPHIC) — 238KB
- g921303ex99_1p17g1.jpg (GRAPHIC) — 291KB
- g921303ex99_1p18g1.jpg (GRAPHIC) — 204KB
- g921303ex99_1p19g1.jpg (GRAPHIC) — 244KB
- g921303ex99_1p1g1.jpg (GRAPHIC) — 153KB
- g921303ex99_1p20g1.jpg (GRAPHIC) — 402KB
- g921303ex99_1p21g1.jpg (GRAPHIC) — 295KB
- g921303ex99_1p22g1.jpg (GRAPHIC) — 360KB
- g921303ex99_1p23g1.jpg (GRAPHIC) — 238KB
- g921303ex99_1p24g1.jpg (GRAPHIC) — 259KB
- g921303ex99_1p25g1.jpg (GRAPHIC) — 181KB
- g921303ex99_1p26g1.jpg (GRAPHIC) — 156KB
- g921303ex99_1p2g1.jpg (GRAPHIC) — 608KB
- g921303ex99_1p3g1.jpg (GRAPHIC) — 428KB
- g921303ex99_1p4g1.jpg (GRAPHIC) — 355KB
- g921303ex99_1p5g1.jpg (GRAPHIC) — 250KB
- g921303ex99_1p6g1.jpg (GRAPHIC) — 301KB
- g921303ex99_1p7g1.jpg (GRAPHIC) — 187KB
- g921303ex99_1p8g1.jpg (GRAPHIC) — 328KB
- g921303ex99_1p9g1.jpg (GRAPHIC) — 253KB
- 0001193125-25-005010.txt ( ) — 10242KB
- vera-20250113.xsd (EX-101.SCH) — 3KB
- vera-20250113_lab.xml (EX-101.LAB) — 18KB
- vera-20250113_pre.xml (EX-101.PRE) — 11KB
- d921303d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Slide presentation entitled "J.P. Morgan Healthcare Conference". 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: January 13, 2025 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer